These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35235412)

  • 1. Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
    Bruno L; Ostinelli A; Waisberg F; Enrico D; Ponce C; Rivero S; Blanco A; Zarba M; Loza M; Fabiano V; Amat M; Pombo MT; Noro L; Chacón M; Coló F; Chacón R; Nadal J; Nervo A; Costanzo V
    JCO Precis Oncol; 2022 Mar; 6():e2100140. PubMed ID: 35235412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
    Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
    Stubbins RJ; Korotev S; Godley LA
    Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
    Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
    Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline
    Nerone M; Rossi L; Condorelli R; Ratti V; Conforti F; Palazzo A; Graffeo R
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group.
    Fountzilas E; Koliou GA; Vozikis A; Rapti V; Nikolakopoulos A; Boutis A; Christopoulou A; Kontogiorgos I; Karageorgopoulou S; Lalla E; Tryfonopoulos D; Boukovinas I; Rapti C; Nikolaidi A; Karteri S; Moirogiorgou E; Binas I; Mauri D; Aravantinos G; Zagouri F; Saridaki Z; Psyrri A; Bafaloukos D; Koumarianou A; Res E; Linardou H; Mountzios G; Razis E; Fountzilas G; Koumakis G
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
    Howie LJ; Singh H; Bloomquist E; Wedam S; Amiri-Kordestani L; Tang S; Sridhara R; Sanchez J; Prowell TM; Kluetz PG; King-Kallimanis BL; Gao JJ; Ibrahim A; Goldberg KB; Theoret M; Pazdur R; Beaver JA
    J Clin Oncol; 2019 Dec; 37(36):3475-3483. PubMed ID: 31560580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of Breast Radiotherapy Among Carriers of
    Modlin LA; Flynn J; Zhang Z; Cahlon O; Mueller B; Khan AJ; Gillespie EF; McCormick B; Stadler ZK; Robson ME; Powell SN; Braunstein LZ
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
    Collins JM; Nordstrom BL; McLaurin KK; Dalvi TB; McCutcheon SC; Bennett JC; Murphy BR; Singhal PK; McCrea C; Shinde R; Briceno JM
    Oncol Ther; 2021 Dec; 9(2):575-589. PubMed ID: 34308518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.